Publication | Closed Access

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Lymphoid NeoplasiaRituximab Versus ChopOncologyMantle-cell LymphomasMetronomic TherapyClinical TrialsPathologyPharmacotherapyNon-inferiority TrialImmunotherapyMedicineRadiation OncologyHealth Sciences